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ABSTRACT
Introduction: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demon-
strated excellent results in the treatment of erectile dysfunction. The effect of sildenafil citrate in the
cavernous arteries of patients with erectile dysfunction has not been established yet. The objective of
this study was to assess the effect of sildenafil citrate in the cavernous arteries of patients with erectile
dysfunction, following an intracavernous injection of alprostadil.
Materials and Methods: 29 male patients, with mean age of 53.8 years (32 to 75 years), were
prospectively evaluated. The mean time with complaint of erectile dysfunction was 50.5 months (6 to
168 months). Each patient was his own control. Patients underwent a measurement of peak systolic
velocity before and after use of sildenafil citrate associated with 5 micrograms of alprostadil, through
ultrasonic velocitometry Knoll/MIDUS® system. In the interval between measurements, approxi-
mately 15 days, patients used 3 tablets of sildenafil at home with their partners.
Results: Using only 5 mcg of alprostadil, average peak systolic velocity was 23.9 cm/s, and
when associated to 50 mg of sildenafil it was 24.8 cm/s. Despite the increase in the flow rate caused
by sildenafil, the difference was not statistically significant, Zcalculated = - 0.695 NS (Wilcoxon test).
Twenty one of the 29 patients (72.4%) showed global improvement in sexual performance with the
use of sildenafil citrate at home. There was not a statistically significant correlation between the
global response to sildenafil citrate and the increase in the peak systolic velocity.
Conclusion: We concluded that, even though the use of 50 mg of sildenafil citrate associated
with 5 mcg of alprostadil provides an increase in the peak systolic velocity of the cavernous arteries,
there was no statistic difference in relation to alprostadil alone. There was no correlation between the
global response to sildenafil and the increase in the peak systolic velocity.
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INTRODUCTION
Erectile dysfunction is the persistent inabil-
ity to reach or maintain an erection that is sufficient
for a satisfactory sexual intercourse (1,2). In Brazil,
some degree of erectile dysfunction was found in
39.8% of the studied population (3).
Until 1996, treatments recommended for
erectile dysfunction were the vacuum devices, the
therapy with injectable vasoactive drugs and penile
prosthesis (4), when the first clinical results with the
use of sildenafil citrate were published (5,6). The re-
sponse according to dosage was 60, 84 and 100%,
respectively with doses of 25, 50 and 100 mg of
sildenafil, compared with a response of 5% from those
who received placebo (7). A significant improvement
of erections following the use of sildenafil citrate was
demonstrated in several trials, reaching a success rate
of 70 to 90% (6-10).
Objectively, the action of sildenafil citrate was
confirmed by penile plethysmography, with a mean dura-
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tion of rigidity above 60% in relation to placebo (11).
The effect of sildenafil citrate in the cavernous arter-
ies’ flow was confirmed in men without complaints
of erectile dysfunction (12), through an increase in
the peak systolic velocity with the use of sildenafil
citrate that was similar to that obtained with papaver-
ine (13,14).
The objective of this study was to assess the
effect of sildenafil citrate in the cavernous arteries of
patients with erectile dysfunction, following an
intracavernous injection of alprostadil.
MATERIALS AND METHODS
A prospective, comparative, clinical trial was
performed, in which the patient was his own control,
in 29 male patients, with ages ranging from 32 to 75
years (mean 53.8 years) and with complaints of erec-
tile dysfunction.
The time since settlement of the erectile dys-
function picture ranged from 6 to 168 months (mean
50.5 month). Laboratory analysis consisted of dos-
age of serum total testosterone, prolactin and fasting
glycemia.
After the patient had fulfilled the inclusion
criteria, we started the study. The first visit aimed
the baseline assessment of cavernous arteries. The
patient was conducted to a special, isolated and com-
fortable room. After some minutes for adapting to
the environment, 5 mcg of alprostadil were applied
by intracavernous route with a 30-gauge needle. The
patient remained resting in this room and with ma-
terial containing visual erotic stimulation available.
Following a 15-minute period, we started the ex-
amination. Patients who did not present a satisfac-
tory erection following the drug application were
excluded from the study and referred to other type
of treatment.
We used ultrasonic velocitometry by the
Knoll/MIDUS system (Urometrics, St Paul, Minne-
sota) for measurement of the peak systolic velocity.
The system is comprised by 2 ultrasonic fixed angle
transducers (60°). The frequency of each transducer
is 8 MHz and it has a measurement capability of blood
flow in amplitude from 1 to 200 cm/s. The transducer
has a focal distance of 1.2 cm (15).
Measurements were obtained in a standard-
ized way in all patients. With the patient in supine
position, the transducers were positioned in the base
of the penis and moved laterally until a consistent
signal was captured by the earphone and viewed in
the computer screen. Data from left and right cavern-
ous arteries were obtained separately. Signals were
recorded in high-speed charts in function of time.
Upon completion of the examination, the pa-
tient received a box containing 4 tablets of sildenafil
citrate 50 mg. The patient was instructed to use 3 tab-
lets at home, with his partner in a period of 15 days,
always one hour before the sexual intercourse. The
fourth tablet should be taken one hour before the next
visit, when a new assessment would be done. The
use of sildenafil at home aimed to assess each patient’s
response to the medication and to compare it with
the results obtained in the second assessment.
Before the patient was released, he was in-
structed about the possibility of priapism, and to come
back to the hospital if the erection lasted for 4 hours
or more. In the second assessment, in average 15 days
after the first one, patients initially answered to the
following question: the use of the medication im-
proved your sexual performance in this period? Yes
or no? Regardless the answer, a new assessment was
performed. Approximately 1 hour after administrat-
ing 50 mg of sildenafil citrate, the patient received 5
mcg of alprostadil by intracavernous route in the pri-
vate room and once more used visual erotic stimula-
tion for 15 minutes, and then was submitted to the
measurement of peak systolic velocity, following the
same steps of the initial assessment.
All data were classified in tables and submit-
ted to statistical analysis.
In order to study potential differences be-
tween the peak systolic velocity of right and left cav-
ernous arteries, both for periods pre- and post-admin-
istration of sildenafil citrate, as well as the average
for the pre-period in relation to the average for the
post-period, we used Wilcoxon non-parametric test
for 2 non-independent samples. In order to study po-
tential associations between the peak systolic veloc-
ity and the patient’s global response to sildenafil cit-
rate, we used the qui-square test (χ2) for association
tables following the Cochran’s restrictions and when
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Figure 1 – Mean values of peak systolic velocity of the cavernous arteries before and after administration of sildenafil citrate.
present, we used Fisher’s exact test. In all cases, the
rejection level for the null hypothesis was always
fixed in a value below or equal to 0.05 (5%). When
the calculated statistic presented significance, we used
an asterisk (*) to characterize it, otherwise, we used
non-significant (NS).
RESULTS
The tests were performed with total coopera-
tion by the patients, who followed the instructions
made. All patients used visual erotic stimulation for
performing the examinations. No patient was ex-
cluded due to side effects or interruption in the fol-
low-up. Patients returned within the established pe-
riod of 15 days, with few exceptions, which did not
compromise the study’s final result.
The measurement of peak systolic velocity
was performed separately for right and left cavern-
ous arteries. We used the simple mean between them
for comparative analysis, after we had compared the
2 sides that were statistically similar (Figure-1).
Mean values increased from 23.9 cm/s to 24.8
cm/s following the use of sildenafil citrate, however
it was not statistically significant in our sampling.
The statistical analysis of data obtained is expressed
in Table-1.
The response to use of sildenafil citrate at
home with the partner was positive in 72.4% of pa-
tients. When the groups are divided by age range, the
response is enhanced for the group < 50 years, pre-
senting 86.67% of yes answers (p = 0.086), Figure-2.
Comparative analyses between the several
variables are presented in Tables-2 and 3.
Adverse events reported by patients were
mild headache in 4 patients (13.8%), gastrointesti-
nal upset in 2 (6.9%) and facial rush in 6 (20.7%).
One patient (3.4%) presented priapism lasting for
6 hours after the second assessment, when
alprostadil was used in combination with sildenafil
citrate. The outcome was favorable, requiring only
puncture and irrigation of the corpora cavernosa
with saline solution, with complete detumescence
(Figure-3).
DISCUSSION
The introduction of sildenafil citrate as an
option for treating the erectile dysfunction changed
urologists’ daily practice. The diagnostic arsenal
used for investigating the patient was gradually re-
placed, and many times on request of the patient
himself, by a simple test of drug use at home with
his partner.
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Table 1 – Statistical analysis of differences between the mean peak systolic velocity of cavernous arteries before and after
use of sildenafil citrate.
N Mean cm/s       Minimal Value             MaximalValue            Wilcoxon Test
Before 29                     23.9                                13                           39
After 29                     24.8                                12                           46.5             Z= -0.695 NS
NS – non significant
Figure 2 – Global response to sildenafil citrate according to age.
The mechanism of action of sildenafil citrate
was already well established at a cellular level, but
there is little information about the effect of the drug
on the cavernous arteries’ flow during the erection
(12-14).
Our sample intended to maximally represent
the outpatient profile for erectile dysfunction. Pa-
tients’ mean age was 53.9 years with a mean time
with complaint of 4.2 years. The methodology for
obtaining the erection used the routine diagnostic
methods for patients with erectile dysfunction. The
drug-induced erection test was the choice method for
baseline assessment of the cavernous arteries’ flow,
and at the same time, it selected the patients who could
continue in the study.
During the interval period between assess-
ments, patients used sildenafil citrate at home for
evaluating their global response to the drug. In this
way, we tried to eliminate the stress of an examina-
tion room inside a hospital, and also to allow the pa-
tient to use the drug in the natural environment where
we intended that the medication would act. The as-
sessment of results of the study’s domiciliary phase
was done with a simple question about improvement
and global satisfaction of sexual performance, which
in our opinion is the patient’s goal. Seventy-two per-
cent of patients reported improvement of erections and
stated that they were satisfied with the use of the drug
at home. On the second assessment of the cavernous
arteries velocitometry, now using sildenafil citrate, we
performed once more the drug-induced erection test
with 5 mg of alprostadil so that the potential advan-
tage obtained with the sildenafil citrate could be as-
sessed in a reliable way. The use of visual erotic stimu-
lation was warranted by the very mechanism of action
of the drug in question. Visual erotic stimulation can
reduce the stress factors inherent to the examination
and thus to improve the erectile response (16).
Our data were initially analyzed by compar-
ing the peak systolic velocity of the left and right cav-
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Table 2 – Individuals with peak systolic velocity values
= 23 cm/s, according to age and global response.
.
Global Response      < 50 Years     > 50 Years     Total
No 0         6             6
Yes 4         7            11
Total 4       13            17
Fisher’s exact test, p = 0.1387 or 13.87%, non-significant.
Table 3 –  Individuals with peak systolic velocity values
> 23 cm/s, according to age and global response, with
statistical results.
Global Response      < 50 Years >
 
50 Years     Total
No 1        1             2
Yes 5        5           10
Total 6        6           12
Fisher’s exact test, p = 0.7727 or 77.27%, non-significant.
Figure 3 – Adverse events.
ernous arteries on the baseline assessment and on the
assessment following the use of sildenafil citrate. On
the baseline assessment, the mean peak systolic veloc-
ity was 23.8 cm/s and 23.2 cm/s for the left and right
sides respectively, Zcalculated = - 0.313 NS (Wilcoxon test)
and on the period following the use of sildenafil cit-
rate, the mean peak systolic velocity was 25.8 cm/s
and 24.8 cm/s for the left and right sides respectively,
Zcalculated = - 0.397 NS (Wilcoxon test).
Since there was no statistically significant dif-
ference between right and left sides, we used the av-
erage between both sides for assessment of changes
obtained with the use of sildenafil citrate. The mean
peak systolic velocity on the baseline assessment was
23.9 cm/s and 24.8 cm/s following the use of sildenafil
citrate. Despite the increase observed, the difference
was not statistically significant, Zcalculated= - 0.695 NS
(Wilcoxon test), probably due to the small number of
patients studied in this sample.
Of the 21 patients who showed improvement
of sexual performance, 11 (52.4%) presented a mean
peak systolic velocity lower or equal to the median
(23 cm/s) and 10 (47.6%) higher than 23 cm/s (p =
0.25 NS, Fisher’s exact test), demonstrating that there
was no relation between the patient’s clinical improve-
ment and the peak systolic velocity.
We analyzed separately those patients with a
mean peak systolic velocity following sildenafil cit-
rate above the median (23 cm/s) as for age and global
response. The result between the groups was identi-
cal. Ten patients responded to sildenafil citrate and 2
did not. Among those who responded, 5 (50%) were
from the group of patients with age under 50 years
and 5 (50%) above or equal to 50 years, and one from
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each group did not respond. There was no difference
between age ranges.
In the groups of individuals aged under 50
years, 9 patients responded to sildenafil citrate, with
4 and 5 patients presenting respectively a peak sys-
tolic velocity lower or equal and higher than 23 cm/s
(p = 0.6 NS, Fisher’s exact test).
This study analyzed the change in the cav-
ernous arteries flow with the use of sildenafil citrate
and its correlation with the patient’s clinical response
to the medication. We did not try to present an objec-
tive confirmation of the drug’s pharmacodynamic ef-
ficacy, also because the characteristics of the study
and the size of the sample did not allow that.
A recent study has assessed the efficacy of
sildenafil citrate in 433 men with the diagnosis of
erectile dysfunction. Among the several parameters
that were studied, the better response to sildenafil
citrate in patients with a diagnosis of veno-occlusive
dysfunction in relation to the intracavernous injec-
tion (17) attracts our attention. The performance of a
cavernosometry could give us some additional data
in order to fundament the role of the sildenafil citrate
in the cavernous veno-occlusive mechanism, and
should be used in future studies.
CONCLUSION
The use of 50 mg of sildenafil citrate does
not provide an additional increase in relation to that
obtained with the use of 5 mcg of alprostadil, of the
peak systolic velocity of the cavernous arteries in
patients with erectile dysfunction, as measured by
ultrasonic velocitometry. There is no correlation be-
tween the patient’s clinical response to 50 mg of
sildenafil citrate and the changes in the peak systolic
velocity of the cavernous arteries in patients with erec-
tile dysfunction.
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